Cargando…
A randomized, triple-blinded controlled clinical study with a novel disease-modifying drug combination in equine lameness-associated osteoarthritis
OBJECTIVE: This study aimed to test a novel treatment combination (TC) (equivalent to sildenafil, mepivacaine, and glucose) with disease-modifying properties compared to Celestone® bifas® (CB) in a randomized triple-blinded phase III clinical study in horses with mild osteoarthritis (OA). Joint biom...
Autores principales: | Skiöldebrand, E., Adepu, S., Lützelschwab, C., Nyström, S., Lindahl, A., Abrahamsson-Aurell, K., Hansson, E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320210/ https://www.ncbi.nlm.nih.gov/pubmed/37416846 http://dx.doi.org/10.1016/j.ocarto.2023.100381 |
Ejemplares similares
-
Salivary biglycan-neo-epitope-BGN(262): A novel surrogate biomarker for equine osteoarthritic sub-chondral bone sclerosis and to monitor the effect of short-term training and surface arena
por: Adepu, S., et al.
Publicado: (2023) -
Serum nerve growth factor in horses with osteoarthritis‐associated lameness
por: Kendall, Anna, et al.
Publicado: (2023) -
Effect of circadian rhythm, age, training and acute lameness on serum concentrations of cartilage oligomeric matrix protein (COMP) neo‐epitope in horses
por: Ekman, S., et al.
Publicado: (2019) -
Cartilage oligomeric matrix protein neoepitope in the synovial fluid of horses with acute lameness: A new biomarker for the early stages of osteoarthritis
por: Skiöldebrand, E., et al.
Publicado: (2017) -
Agmatine Administration Effects on Equine Gastric Ulceration and Lameness
por: Taguchi, Takashi, et al.
Publicado: (2022)